Sign In
Buy SLP
$16.17
-0.600 (-3.58%)
At Close: Jun 03, 2026
Simulations Plus: Better Quarter, Same Doubts
12:14pm, Wednesday, 15'th Apr 2026
Simulations Plus, Inc. remains a Hold as business improvement is insufficient to warrant a Buy, despite stabilization post-earnings. Q2 2026 revenue grew 8% YoY to $24.3M, with strong software renewal
Reviewing Smith Micro Software (NASDAQ:SMSI) & Simulations Plus (NASDAQ:SLP)
02:17am, Wednesday, 15'th Apr 2026
Smith Micro Software (NASDAQ: SMSI - Get Free Report) and Simulations Plus (NASDAQ: SLP - Get Free Report) are both small-cap computer and technology companies, but which is the better business? We wi
Simulations Plus: Down Substantially, Not An Automatic Buy
06:18am, Sunday, 12'th Apr 2026
Simulations Plus trades at decade lows as investors question growth and AI disruption risks. SLP's Q2 sales grew 8% to $24.3M, but the full-year revenue outlook is flat to up 4%, with earnings guidanc
Why Simulations Plus Stock Inched Higher Today
05:33pm, Friday, 10'th Apr 2026
It notched beats on both revenue and profitability in its fiscal second quarter. On a negative note, it cut its net income forecast for the full fiscal year.
Simulations Plus Q2 Earnings & Revenues Beat, Jump Y/Y, Shares Soar
11:21am, Friday, 10'th Apr 2026
SLP beats fiscal Q2 earnings and posts solid revenue growth, but cuts full-year EPS view even as backlog rises and margins expand across software and services.
Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript
07:12pm, Thursday, 09'th Apr 2026
Simulations Plus, Inc. (SLP) Q2 2026 Earnings Call Transcript
Simulations Plus (SLP) Beats Q2 Earnings and Revenue Estimates
06:15pm, Thursday, 09'th Apr 2026
Simulations Plus (SLP) came out with quarterly earnings of $0.35 per share, beating the Zacks Consensus Estimate of $0.27 per share. This compares to earnings of $0.31 per share a year ago.
Simulations Plus Reports Second Quarter Fiscal 2026 Financial Results
04:05pm, Thursday, 09'th Apr 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
JPMorgan Chase & Co. Boosts Holdings in Simulations Plus, Inc. $SLP
04:59am, Monday, 06'th Apr 2026
JPMorgan Chase and Co. boosted its stake in shares of Simulations Plus, Inc. (NASDAQ: SLP) by 154.7% during the undefined quarter, according to its most recent filing with the SEC. The firm owned 167,
Simulations Plus Announces Second Quarter Fiscal Year 2026 Earnings and Conference Call Date
04:05pm, Thursday, 26'th Mar 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”, “SLP”), a global leader in model-informed and AI-accelerated drug development that adva
Simulations Plus Announces Strategic Collaboration Programs for AI-Enabled Modeling
07:55am, Thursday, 26'th Mar 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
Simulations Plus Convenes Industry and Regulatory Leaders to Define Responsible AI in MIDD
07:55am, Tuesday, 03'rd Mar 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
ROSEN, A LONGSTANDING FIRM, Encourages Simulations Plus, Inc. Investors to Inquire About Securities Class Action Investigation - SLP
04:22pm, Wednesday, 11'th Feb 2026
New York, New York--(Newsfile Corp. - February 11, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Sim
Simulations Plus Announces Extensions of U.S. FDA and NIEHS Research Collaborations
06:45pm, Monday, 09'th Feb 2026
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development
New York, New York--(Newsfile Corp. - February 9, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simu
